Dipòsit Digital de Documents de la UAB
Publicación
Artículo científico (JournalArticle)
Reversion of metabolic dysfunction-associated steatohepatitis by skeletal muscle-directed FGF21 gene therapy
The highly prevalent metabolic dysfunction-associated steatohepatitis (MASH) is associated with liver steatosis, inflammation, and hepatocyte injury, which can lead to fibrosis and may progress to hepatocellular carcinoma and death. New treatment modalities such as gene therapy may be transformative for MASH patients. Here, we describe that one-time intramuscular administration of adeno-associated viral vectors of serotype 1 (AAV1) encoding native fibroblast growth factor 21 (FGF21), a key metabolic regulator, resulted in sustained increased circulating levels of the factor, which mediated long-term (.
Proyecto:
Agencia Estatal de Investigación SAF2017-86266R
,
Agència de Gestió d'Ajuts Universitaris i de Recerca 2017/SGR-1508
,
Agència de Gestió d'Ajuts Universitaris i de Recerca 2021/SGR-01012
,
Ministerio de Sanidad y Consumo CB07/08/0037
,
Ministerio de Economía y Competitividad BES-2015-075799
,
Ministerio de Educación FPU14/05268
,
Cultura y Deporte FPU12/03589